Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, September 2011, Pages: 61

Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global therapeutics market. The report identifies the key trends shaping and driving the global dysmenorrhea therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dysmenorrhea therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global dysmenorrhea therapeutics market was valued at $4.1 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% over the next eight years to reach $4.8 billion by 2018. This low value growth in the dysmenorrhea therapeutics market is primarily attributed to the high usage of low priced OTC (Over-The-Counter) and off-label drugs and the low penetration of the patented product Celebrex (celecoxib). However, an increase in the patient population will be the primary contributor to the growth of the market in the forecast period.

Scope

The report provides information on the key drivers and challenges of the dysmenorrhea market. Its scope includes -
- Annualized global dysmenorrhea market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as low dose estrogen-progesterone, NSAID, vasopressin antagonist, cytochrome inhibitor, phosphodiesterase inhibitor, sodium channel blockers and prostaglandin inhibitors.
- Analysis of the current and future competition in the global dysmenorrhea therapeutics market. Key market players covered are Nobelpharma and Vantia Therapeutics. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the dysmenorrhea therapeutics market.
- Analysis of key recent licensing and partnership agreements in dysmenorrhea therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dysmenorrhea therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global dysmenorrhea therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global dysmenorrhea therapeutics market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

1
1

1.1 List of Tables
1.2 List of Figures
2 Dysmenorrhea Therapeutics: Introduction
2.1 Disease Overview
2.1.1 Primary Dysmenorrhea
2.1.2 Secondary Dysmenorrhea
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Quality of Life
2.2.3 Pharma-economic Burden
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Clinical Approach
2.5.2 Physical Examination
2.5.3 Investigational Approach
2.6 Treatment and Management Options
2.6.1 Non Pharmacological Treatment
2.6.2 Pharmacological Treatment
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 DysmenorrheaTherapeutics: Market Characterization
3.1 Overview
3.2 Dysmenorrhea Therapeutics Market Size (2005-2010) – Global
3.3 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Global
3.4 Dysmenorrhea Therapeutics Market Size (2005-2010) – The US
3.5 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – The US
3.6 Dysmenorrhea Therapeutics Market Size (2005-2010) – France
3.7 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – France
3.8 Dysmenorrhea Therapeutics Market Size (2005-2010) – Germany
3.9 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Germany
3.10 Dysmenorrhea Therapeutics Market Size (2005-2010) – Italy
3.11 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Italy
3.12 Dysmenorrhea Therapeutics Market Size (2005-2010) – Spain
3.13 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Spain
3.14 Dysmenorrhea Therapeutics Market Size (2005-2010) – The UK
3.15 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – The UK
3.16 Dysmenorrhea Therapeutics Market Size (2005-2010) – Japan
3.17 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Japan
3.18 Drivers and Barriers for the Dysmenorrhea Therapeutics Market
3.18.1 Drivers for the Dysmenorrhea Therapeutics Market
3.18.2 Barriers for the Dysmenorrhea Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 Dysmenorrhea Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Dysmenorrhea Therapeutics Market
4.3.1 Diclofenac Potassium
4.3.2 Celebrex (Celecoxib)
4.3.3 Naproxen Sodium
4.4 Key Takeaway
5 Dysmenorrhea Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Dysmenorrhea Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 Dysmenorrhea Therapeutics – Phase III Pipeline
5.3.2 Dysmenorrhea Therapeutics – Phase II Pipeline
5.3.3 Dysmenorrhea Therapeutics – Phase I Pipeline
5.3.4 Dysmenorrhea Therapeutics – Pre-Clinical Pipeline
5.3.5 Technology Trends Analytic Framework
5.4 Dysmenorrhea Therapeutics Market – Pipeline by Mechanism of Action
5.5 Molecule Profile for Promising Drugs under Clinical Development
5.5.1 NPC-01
5.5.2 VA111913 TS
5.6 Key Takeaway
6 Dysmenorrhea Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, the EU and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Dysmenorrhea Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Dysmenorrhea Therapeutics: Implications for Future Market Competition
8 Dysmenorrhea Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Nobelpharma Co., Ltd
8.2.2 Vantia Therapeutics
9 Dysmenorrhea Therapeutics: Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: Dysmenorrhea Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 2: Dysmenorrhea Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 3: Dysmenorrhea Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 4: Dysmenorrhea Therapeutics Market, The US, Forecasts ($m), 2010-2018
Table 5: Dysmenorrhea Therapeutics Market, France, Revenue ($m), 2005–2010
Table 6: Dysmenorrhea Therapeutics Market, France, Forecasts ($m), 2010-2018
Table 7: Dysmenorrhea Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 8: Dysmenorrhea Therapeutics Market, Germany, Forecasts ($m), 2010-2018
Table 9: Dysmenorrhea Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 10: Dysmenorrhea Therapeutics Market, Italy, Forecasts ($m), 2010-2018
Table 11: Dysmenorrhea Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 12: Dysmenorrhea Therapeutics Market, Spain, Forecasts ($m), 2010-2018
Table 13: Dysmenorrhea Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 14: Dysmenorrhea Therapeutics Market, The UK, Forecasts ($m), 2010-2018
Table 15: Dysmenorrhea Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 16: Dysmenorrhea Therapeutics Market, Japan, Forecasts ($m), 2010-2018
Table 17: Mean TOTPAR-8 and SPID-8 values for Celebrex, Naproxen Sodium and Placebo
Table 18: Dysmenorrhea Therapeutics – Phase III Pipeline, 2011
Table 19: Dysmenorrhea Therapeutics – Phase II Pipeline, 2011
Table 20: Dysmenorrhea Therapeutics – Phase I Pipeline, 2011
Table 21: Dysmenorrhea Therapeutics – Pre-Clinical Pipeline, 2011
Table 22: Dysmenorrhea Therapeutics – Clinical Trials by Country, 2011
Table 23: Dysmenorrhea Therapeutics - Clinical Trials by Phase, 2011
Table 24: Dysmenorrhea Therapeutics - Clinical Trials by Status, 2010
Table 25: Dysmenorrhea Therapeutics - Prominent Sponsors, 2011
Table 26: Dysmenorrhea Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 27: Nobelpharma – Pipeline, 2011
Table 28: Vantia Therapeutics – Pipeline, 2011

1.2 List of Figures
Figure 1: Etiology of Dysmenorrhea
Figure 2: Pathophysiology of Primary Dysmenorrhea
Figure 3: Treatment Pattern of Primary Dysmenorrhea
Figure 4: Referral Pathway for Dysmenorrhea
Figure 5: Dysmenorrhea Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 6: Dysmenorrhea Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 7: Dysmenorrhea Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 8: Dysmenorrhea Therapeutics Market, The US, Forecast ($m), 2010-2018
Figure 9: Dysmenorrhea Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 10: Dysmenorrhea Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 11: Dysmenorrhea Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 12: Dysmenorrhea Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 13: Dysmenorrhea Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 14: Dysmenorrhea Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 15: Dysmenorrhea Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 16: Dysmenorrhea Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 17: Dysmenorrhea Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 18: Dysmenorrhea Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 19: Dysmenorrhea Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 20: Dysmenorrhea Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 21: Opportunity and Unmet Need in the Dysmenorrhea Therapeutics Market
Figure 22: Dysmenorrhea Therapeutics – Strategic Competitor Assessment, 2011
Figure 23: Dysmenorrhea Therapeutics – Pipeline by Phase of Development, 2011
Figure 24: Dysmenorrhea Therapeutics – Technology Trends Analytics Framework, 2011
Figure 25: Dysmenorrhea Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 26: Dysmenorrhea Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 27: Clinical Trial Details of NPC-01
Figure 28: Clinical Trial Details of VA111913 TS
Figure 29: Dysmenorrhea Therapeutics – Clinical Trials by Country, 2011
Figure 30: Dysmenorrhea Therapeutics - Clinical Trials by Phase, 2011
Figure 31: Dysmenorrhea Therapeutics - Clinical Trials by Status, 2011
Figure 32: Dysmenorrhea Therapeutics - Overall Sponsors, 2011
Figure 33: Dysmenorrhea Therapeutics - Prominent Sponsors, 2011
Figure 34: Dysmenorrhea Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 35: Dysmenorrhea Therapeutics Market, Drivers and Restraints 2011
Figure 36: Implications for Future Market Competition in the Dysmenorrhea Market, 2011
Figure 37: Dysmenorrhea Therapeutics Market – Pipeline by Company, 2011

GlobalData, the industry analysis specialist, has released its new report, “Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global therapeutics market. The report identifies the key trends shaping and driving the global dysmenorrhea syndrome therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dysmenorrhea syndrome therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Dysmenorrhea Therapeutics Market to Show Low Value Growth until 2018

GlobalData estimates that the global dysmenorrhea therapeutics market was valued at $4.1 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% over the next eight years to reach $4.8 billion by 2018. This low value growth in the dysmenorrhea therapeutics market is primarily attributed to the high usage of low priced OTC (Over-The-Counter) and off-label drugs and the low penetration of the patented product Celebrex (celecoxib). However, an increase in the patient population will be the primary contributor to the growth of the market in the forecast period.

Dysmenorrhea Therapeutics Market, Global, Revenue and Forecasts ($m), 2005-2018

Source: GlobalData, Andersch B, Milsom I, “An epidemiologic study of young women with dysmenorrhea”, American Journal of Obstetrics and Gynecology, 1982; Messing K et.al., “Factors associated with dysmenorrhea among workers in French poultry slaughterhouses and canneries”, Journal of Occupational Medicine 1993; Helmut Barmuinger, “Results of the study BEDY: The effect of CMA on dysmenorrhea and other cycle related components”, Journal of Gyenecological Endocrinology, 2009; E. Anastasakis et. al., “Menstrual Problems in University Students: An Electronic Mail Survey”, Department of Obstetrics and Gynecology, 2008.

Dysmenorrhea Therapeutics Market has Low Unmet Need

GlobalData has found that the dysmenorrhea therapeutics market has a low unmet need, which implies that the market is well-served by the current marketed products and that potential market entry for new drugs is limited. The current dysmenorrhea treatment options are mainly dominated by OTC, off-label and generic drugs which have high safety and efficacy profiles and capture a large market share.

However, the residual unmet need can be satisfied by novel therapies which will provide better symptomatic relief than the current marketed products.

Nobelpharma Co., Ltd
Vantia Therapeutics

Customers who bought this item also bought

• Dysmenorrhea - Pipeline Review, H2 2012
• Dysmenorrhea - Pipeline Review, Q4 2010
• Primary Dysmenorrhea - Pipeline Review, Q4 2010
• Global Migraine Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• Global Schizophrenia Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
• RNA Interference (RNAi) - Global Strategic Business Report
• Intranasal Drug Delivery - Global Business Strategic Report
• Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• CNS Therapeutics - Global Strategic Business Report